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Nicolas M. Van Mieghem, MD,y Aad van der Lugt, MD, PHDzSEE PAGE 1146U pdated guidelines on valvular heart diseasefrom both sides of the Atlantic haveendorsed transcatheter aortic valve replace-
ment (TAVR) for treatment of symptomatic patients
with severe aortic valve stenosis (AS) at (very) high
risk for post-operative mortality (1,2). Following the
publication of the PARTNER (Placement of AoRtic
TraNscathetER Valves) Cohorts A and B randomized
trial results, the stigma of excessive cerebrovascular
events was associated with TAVR (3,4). Of note, the
difference in major or disabling stroke between
TAVR and surgical aortic valve replacement (SAVR)
never was signiﬁcant, and after 3 years, the overall
number of cerebrovascular events in both treatment
arms converged. Earlier this year, the U.S. CoreValve
High Risk Study wiped this apparent inaccuracy away
because there appeared numerically even fewer cere-
brovascular events in the TAVR arm as compared with
SAVR at both 30 days and 1 year (5). Case closed?
Probably not! Major or disabling stroke rates of 3.8%
and 5% in PARTNER Cohorts A and B, respectively,
and 2.3% and 3.9% in the U.S. CoreValve Extreme
Risk and High Risk studies should not be taken for
granted, and efforts to reduce stroke rates to an abso-
lute minimum should be encouraged (3–6).
Crossing a degenerated aortic valve with any kind
of guidewire or catheter is associated with a deﬁnite
risk of mostly subclinical cerebral embolization, and
systematic diffusion-weighted brain magnetic reso-
nance imaging (DW-MRI) examination after TAVR
revealed new ischemic brain lesions in approximately*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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Healthcare.80% of patients, double what is reported after SAVR
(7–9). These, at ﬁrst glance, subclinical events may
not be so innocent because neurocognitive decline
and premature dementia are linked to silent brain in-
farcts (10). Especially because the TAVR technology
is shifting to lower-risk and thus younger patient
populations, these astronomical numbers of MRI-
detected brain (micro-)infarcts post-TAVR can hardly
be acceptable. The disclosure of the histopathology
of what exactly embolizes to the brain during TAVR
could help focus research efforts (11). Intuitively, it
makes sense to install a barrier at the origin of the
major brain arteries and ﬁlter or deﬂect debris stem-
ming from atherosclerotic plaques or the aortic valve.This issue of JACC: Cardiovascular Interventions
features the PROTAVI-C pilot study (12), which
assessed procedural safety, technical feasibility, and
efﬁcacy of the Embrella Embolic Deﬂector (EED) sys-
tem (Edwards Lifesciences, Irvine, California). The
study follows prior publications on safety and feasi-
bility of other embolic protection devices (13,14). A
total of 42 patients underwent TAVR while receiving
the EED device and were compared with 12 patients
who underwent TAVR without EED. The EED
appeared user friendly. All attempts to implant the
device were successful without extending the overall
TAVR procedure time (median time to deploy the EED
system was just 2 min). The target ostia of the
brachiocephalic trunk and left common carotid were
covered in all but 1 patient.
All but 2 patients had a DW-MRI at baseline and
per-procedural transcranial Doppler (TCD) moni-
toring. The high rate of successful TCD recordings is
remarkable and somewhat unexpected, given the
mean age of the study population (well above
80 years of age). In our TAVR practice, suboptimal
acoustic windows preclude interpretable TCD
signals in a considerable number of octogenarians.
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1157Nonetheless, the TCD data corroborated previous TCD
insights that transcatheter valve positioning and im-
plantation were associated with the majority of high-
intensity transient signals (HITS). The impact of EED
use on TCD ﬁndings is sobering: the total number of
HITSwas signiﬁcantly higher in patients with EED, and
the introduction of the EED was associated with more
HITS than speciﬁc TAVR-related maneuvers such as
balloon valvuloplasty or the navigation of the trans-
catheter valve delivery system across the aortic arch.
Follow-up DW-MRI within 7 days was performed in
80% (34 of 42) of patients in the EED cohort and in
50% (6 of 12) of the control group and in 62% and 42%
at 30 days, respectively. MRI ﬁndings within 1 week
of the procedure conﬁrm previous reports that cere-
bral embolization is simply ubiquitous in patients
undergoing TAVR. EED had no impact on the overall
ischemic cerebral lesion volume and was associated
with at least numerically more new lesions per pa-
tient (7.5 vs. 4). Conversely, the median volume per
lesion was smaller, but the mean lesion volume per
patient was similar. Of note, timing of the ﬁrst brain
MRI post-TAVR varied with a median interval of
3 days (IQR: 2 to 5 days). This may have considerable
impact on study results and is a fundamental limita-
tion to the study ﬁndings because size and number of
lesions could change considerably between 1 and
7 days post-procedure. Also the ﬁeld strength of the
MRI scanners was not mentioned. It would make a
difference if a 1.5-T or a 3-T scanner was used. A 3-T
scanner is more sensitive and would yield an even
higher lesion detection rate.
Remarkably, all lesions had vanished as docu-
mented by follow-up MRI at 30 days. How to explain
this discrepancy? The MRI compliance rate at 30 days
was low, especially in the no-device arm, and pre-
cludes any ﬁrm conclusions. Indeed Kahlert et al. (9)
demonstrated that acquired lesions were still visible
by brain MRI 3 months post-TAVR in 20% of patients
undergoing TAVR. Conceivably, the high dropout rate
in this study may explain why detectable new (micro-)
infarcts could have been missed. It’s also important to
realize that DW-MRI is highly sensitive in identifying
cerebral ischemia, yet it may not be easy to discern
transiently ischemic brain tissue from completely
infracted tissue at a relatively early stage. Other MRI
techniques, for example, perfusion weighted imaging
with intravenous gadolinium and transversal ﬂuid-
attenuated inversion recovery, can assess cerebral
blood dynamics (volume, ﬂow, and so on) and uncover
hypoperfusion in much larger areas of tissue than
suggested by DW-MRI and thus identify a larger area of
tissue at risk for infarction. Most probably, the new
brain lesions in this study were relatively small(median lesion volume 30 mm3, IQR: 20 to 50 mm3)
and represented brain ischemia, but not infarction,
and therefore, not surprisingly, most of the lesions had
disappeared by 30 days.
The value of embolic protection in other areas of
medicine, for example, carotid stenting is conﬂicting
and deﬁnitely not globally accepted. Yet TAVR argu-
ably comes with more thorough tissue instrumenta-
tion that could lead to dislodgment of considerable
pieces of debris as shown in recent histopathologic
studies (11). This may justify some sort of barrier
protection. Broadly, 2 embolic protection concepts
are under study. The EED and the Triguard (Keystone
Heart, Tel Aviv, Israel) are embolic deﬂectors. The
Sentinel cerebral protection system (Claret Medical,
Santa Rosa, California) consists of 2 separate ﬁlters in
the brachiocephalic trunk and the left common
carotid artery, respectively, and is an embolic capture
device. It has the additional feature of not only
capturing debris, but also removing it from the body.
The question remains whether use of embolic pro-
tection devices during TAVR reduces cerebral embo-
lization and whether embolic deﬂection would be
different from ﬁlter-based embolic protection.
One may wonder whether this pilot study on cere-
bral protection with EED has spurred more contro-
versy than proof of concept. Indeed, the fact that EED
did not affect total new brain lesion volume nor
changed the mean lesion volume per patient, yet was
associated with more HITS by TCD, may suggest
futility. The EED may generate a paradoxical increase
in microembolic load by disintegrating macroemboli
into smaller microemboli that can pass through the
pores of the device (100 mm) or through gaps between
the EED and the vessel wall. Also, thrombus may form
on the device or secondary to arterial wall damage
induced by the device, and slow-ﬂow distal to the EED
may occur if the pores are obstructed and normal
antegrade ﬂow is hampered. Furthermore, the conﬁr-
mation that these new brain lesions documented by
DW-MRI seemed transient does not mean that these
lesions are negligible and irrelevant. The truth of
the matter is that the brain experienced an ischemic
insult, and its deﬁnite impact is uncertain.
Rightfully, the authors of the PROTAVI-C Pilot study
(12) alluded to the need for larger randomized studies
to settle the verdict on EED because for the time being,
it is not clear how embolism proof EED really is.
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